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sUMMarY
the introduction in the mid 1990’s of highly active anti-retroviral drugs therapy 
(HAART) in the treatment of human immunodeficiency virus (HIV) infection has 
significantly changed the course, manifestation of HIV disease and improved the life 
expectancy of  HiV infected patients .
the consequence of longer survival has manifested increasing rates of co-morbid 
diseases and aroused interest in the interaction of HiV and aging
the pathogenesis of the resultant conditions though not fully understood is likely 
multifactorial and may be related to direct effect of the HiV  virus and associated 
immunodeficiency, underlying opportunistic events, immunoactivation ,related 
vasculopathies and inflammatory processes and toxic effects of anti-retroviral 
agents
Bone disorders as such osteopaenia, osteoporosis and bone fractures, osteonecrosis and 
accompanying metabolic changes, has been reported with increasing frequency.
We report two cases of patients known to be HIV positive and on HAART who presented 
with hip pain. The first patient had radiological evidence of osteonecrosis (avascular 
necrosis) of the head of femur, and second patient who presented with acute sudden 
onset pain had fracture of the neck of femur.
Literature is reviewed to elucidate possible mechanism of disease and a brief 
consideration of possible therapy is discussed.
case repOrt 1
 
aKn, a 38 year old HiV positive black male presents 
with one month’s history of left hip pain. Over the last 
6 days he has noted increasing intensity of this pain 
with associated radiation to the buttock and left inner 
thigh. the pain is unbearable on exerting weight and 
he has significant limitation of movement.
 aKn was treated for pulmonary tuberculosis 
five years ago with and intensive phase of rifampicin, 
isoniazid , pyrazinamide and ethambutol for two 
months followed by four months  of rifampicin and 
isoniazid in the continuation phase.
 He tested positive for HiV two years ago 
following admission to hospital with history of 
shortness of breath, fever, and non-productive 
cough chest pain and weight loss. during that 
admission, laboratory test revealed anaemia of 
8.5gm/dl, leucocytosis of 19.6x10⁹/l. His creatinine 
was 156μmol/l with both alanine aminotransferase 
and aspartate aminotransferase 2.5 x above normal 
values. LdH was not done. cd4+ was 137/ml by 
flow cytometry , with both hepatitis B and C markers 
screening negative.  
 a chest radiograph was suggestive of military 
tuberculosis and with a differential diagnosis of 
pneumocystiis pneumonia. the patient was retreated 
with anti-tuberculosis drugs and empirically given 
high dose trimethoprim/sulfamethoxazole and 
prednisone for three weeks. He improved and was 
discharged home for follow up in the HiV clinic.
 radiograph of the hip during his last presentation 
was reported to be consistent with avascular necrosis 
of the femoral head. He improved following treatment 
with non-steroidal anti-inflammatory drug therapy 
and was discharged while ambulating on crutches 
for definitive care by the orthopaedic surgeons
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figure 1
Reticulo-nodular opacities on X-ray of the chest
figure 2
Osteonecrosis head of the left femur
case repOrt 2
a 30 years old HiV positive black female nW, had 
been on highly active anti-retroviral therapy with 
a regimen comprising stavudine, lamivudine and 
efavirenz over the last two years. Her nadir cd4+ 
count at time of initiation of therapy was 13cells/ml. 
there were no reports of her treatment follow up. 
She presented with acute spontaneous hip pain 
with severe exacerbation on movement. nW also 
had shortness of breath. noted to have features of 
lipodystrophy, her temperature was 36.50c, respiratory 
rate of 25/min and a blood pressure of 110/70mmHg. 
She had no calf swelling or tenderness.
 Laboratory tests included normal blood counts, 
normal serum amylase and a raised serum lactate of 
8.0 mmol/l.  radiograph documented osteopaenia 
with fracture of the neck of left femur.  Her disease 
L
progression was rapid and she died within 24 hours 
of admission.
figure 3
Fracture neck of left femur in patient with osteopenia. 
Both hip joints demonstrate radiologic changes
discUssiOn
the association of bone disease and HiV has 
been increasingly observed in the era of highly 
active antiretroviral therapy (Haart) as patient 
life expectancy rises.  Osteopaenia, osteoporosis, 
bone fractures and ost eonecrosis are some of the 
documented bone disorders recognised as HiV 
complications. With the rising uptake of Haart and 
consequent survival benefits of treatment, an older 
HIV patient population may present significant rise 
in bone disease and necessitate strategic public health 
management interventions.
 Mri studies have recorded osteonecrosis in 4.4 
% of patients, which is much higher than 0.01 -0.135% 
prevalence seen in the general population (1, 2).this 
may impact on the national health budgets as it may 
represent  a large need for surgical intervention 
particularly in sub-Saharan africa where the burden 
of HiV disease is still quite high.
 the cause of bone disease remains unclear 
but some of the proposed mechanisms of bone 
disease include; direct effects of the HiV virus 
and associated immunodeficiency, underlying co-
infections and co-morbidity, immune activation 
coupled with inflammation, co-agulopathies and 
associated vascular insufficiency and antiretroviral 
drug toxicities (3).
 direct effect of the HiV virus in the causation 
of osteopaenia and osteoporosis may be due 
to production of pro-inflammatory cytokines 
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responsible for osteoclast activation and consequent 
bone resorption.  Low levels of bone formation marker 
osteocalcin, has been seen in Haart naïve advanced 
HiV disease, suggesting that HiV has independent 
effect on bone metabolism (4, 5).
 Both the patients presented in the case reports 
had advanced HiV disease. the observed bone disease 
could have been attributable to direct effect of the 
HiV virus since the patients presented with relatively 
long duration of illness and opportunistic events 
consistent with WHO stage 3/4 disease .However a 
few question beg to be answered. could the interaction 
of traditional risk factors of osteoporosis in this case 
prolonged use of corticosteroids in patient case report 
1, with HiV viral infection and possible Haart 
related toxicities increase the risk of bone disease? 
Metabolic changes related to Haart have been 
shown to have a causal association with osteopenia 
and osteonecrosis (6). could the mitochondrial 
toxicity of the drug regimen used in this patient or the 
possible consequent dyslipidemia explain the bone 
pathology? is lipodystrophy predictive of higher risk 
of bone disease?
 patients on long periods of stavudine exposure 
have a significant risk of developing lipodystrophy 
and hyperlactataemia both being related to its high 
mitochondrial toxicity. Higher levels of lactate 
secondary to nucleoside reverse transcriptase 
inhibitors therapy have been found to be associated to 
osteopenia in HiV infected men (6). the use of Haart 
regimen containing stavudine, a highly mitochondrial 
toxic di-deoxynucleoside for a duration exceeding one 
year in both patients, with our second patient clearly 
manifesting lipodystrophy and lactic acidosis as 
evidence of drug toxicity may incriminate stavudine 
in the causation of osteopaenia and osteonecrosis. 
 the World health organization (WHO) guidelines 
for treatment of HiV infection in resource constrained 
settings 2010 and 2013 (7, 8). Have recommended 
the use of tenofovir based regimen replacing the 
thymidine analogue based as preferred first line 
intervention. this is because it offers lower toxicity, 
good therapeutic strategy in populations with high 
hepatitis B co-infection and better Haart sequencing 
options. despite lower mitochondrial toxicity, 
tenofovir may be associated with greater degree of 
short term loss of bone density than other antiviral 
drugs (9) . it would be important to evaluate the impact 
of switching from use of thymidine analogue based 
therapy to tenofovir on the incidence of osteopaenia 
and osteonecrosis as the national guidelines now 
recommend tenofovir as our preferred first line 
agent.   the needs to consider the use of abacavir or 
raltegravir as alternatives to tenofovir or use of these 
agents in treatment simplification in patients at high 
risk of kidney and bone disease is likely to provide 
significant consideration in planning of national 
guideline (10)  . 
 controversy still exists on the independent role 
of protease inhibitors in osteopaenia, osteoporosis and 
osteonecrosis with some studies reporting benefit of 
protease inhibitor use and other indicating increasing 
bone loss. (11-13). Matos et.al in their study suggests 
that protease inhibitors play a role in osteonecrosis 
through a tendency to cause hyperlipidemia (11, 12). 
a study by Sharma et al reports that bone loss among 
HiV-infected middle aged women was possibly 
mitigated by use of protease inhibitors with longer 
use appearing to be protective in gain in bone mineral 
density (13). there is great need to establish the varied 
role of different protease inhibitors on osteoblast 
activity,osteoclast differentiation and function and 
calcium deposition. this would help rationalise the 
selection of protease inhibitor particularly when 
considering therapy for patients with traditional risk 
factors of bone disease and those above the age of 50 
years.
 Other valuable considerations that would 
accelerate bone loss include nutritional deficiencies 
and in particular low levels of calcium and vitamin 
d and traditional risk factors of bone disease such as 
alcohol abuse, hyperlipidemias, sickle cell anaemia 
,coagulopathies, hyperuricemia and connective 
tissue disorders. changes in vitamin d metabolism 
with deficit in one, 25 dihydroxycholecalciferol have 
been reported in hiv infected patients. treatment 
of calcium or vitamin D deficiency in HIV positive 
patients on Haart has favorable effects on bone 
density (14) .We need to establish the prevalence 
of vitamin D and calcium deficiency in treatment-
naïve and Haart exposed patients in our setting 
to help inform and rationalise calcium and vitamin 
d supplementation.
 Key interventions in addressing bone health 
in HiV infected patients will therefore involve 
rationalising the selection of Haart regimen, 
paying considerable attention to the risk and benefit 
use of corticosteroids in patients with opportunistic 
diseases, nutritional supplementation and lifestyle 
adjustments  that address the impact of aging and 
immobility on bone disease
 the two patients we have presented would 
benefit from imaging of other joints since hip disease 
will present with bilateral involvement in a good 
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proportion of patients, knee, ankle and shoulder joint 
may also be affected .Multi-joint involvement is not 
infrequent ( 15)  in addition to calcium and vitamin 
d supplementation, some antiresorption agent such 
as oestrogens,calcitonin ,bisphosphonates  and bone 
formation stimulating agents such as sodium fluoride 
and ptH have been used in therapy of bone disease in 
these patients. Surgical decompression, osteotomies 
and arthroplasty may be vital; studies on surgical 
outcomes appear to indicate that total hip replacement 
in HiV positive patients is not worse than that of HiV 
negative patients (16)
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